Keywords: Biotherapeutics; Gene and cell therapy; Pharmacokinetics; Non-clinical safety; Immunogenicity; Cross-reactive species; ATMP; advanced therapy medicinal products; CAR; chimeric antigen receptor; CD; cluster of differentiation; CMC; chemistry manufacturing
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ADA; Anti-drug antibody(ies); ADCC; Antibody-dependent cellular cytotoxicity; AE; Adverse event; CBA; Cell-based assay; CDC; Complement dependent cytotoxicity; CLB; Competitive ligand binding; EIP; European Immunogenicity Platform; EIP-AWG; European Immun
Photon counting LiDAR: An adaptive ground and canopy height retrieval algorithm for ICESat-2 data
Keywords: ICESat-2; Photon classification; Photon counting LiDAR; ATLAS; MABEL; Canopy height; Terrain elevation;
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Keywords: CD3 bispecific; MABEL; First-in-human dose; Oncology drug development; FIH; first-in-human; CRA; cytokine release assay; CRS; cytokine release syndrome; GLP; good laboratory practice; HHD; highest human dose; HNSTD; highest non-severely toxic dose; IB; In
Research ArticleFirst-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B
Keywords: NTCP; sodium taurocholate co-transporting polypeptide; HBV; hepatitis B virus; CHB; chronic hepatitis B; HDV; hepatitis D virus; DSMB; data and safety monitoring board; MABEL; minimal anticipated biologic effect level; AE; adverse event; ECG; electrocardi
An FDA oncology analysis of immune activating products and first-in-human dose selection
Keywords: MABEL; Immune oncology; First-in-human dose; ADCC; antibody-dependent cellular cytotoxicity; CRA; cytokine release assay; CRS; cytokine release syndrome; DLT; dose limiting toxicity; EMA; European Medicines Agency; FIH; first-in-human; HHD; highest human
Landsat 8 and ICESat-2: Performance and potential synergies for quantifying dryland ecosystem vegetation cover and biomass
Keywords: OLI; TM; ATLAS; ICESat-2; MABEL; Above-ground biomass; Shrub;
Testing the ice-water discrimination and freeboard retrieval algorithms for the ICESat-2 mission
Keywords: ICESat-2; MABEL; Sea ice; Polar oceans; Freeboard; Lidars;
Prospects of the ICESat-2 laser altimetry mission for savanna ecosystem structural studies based on airborne simulation data
Keywords: Photon counting lidar; ICESat-2; MABEL; MATLAS; Savanna; Canopy height
Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme
Keywords: anticorps monoclonaux; essais cliniques, phase I; essais cliniques, phase II; essais cliniques, phase IV; AcMo; anticorps monoclonaux; ADCC; antibody dependent cellular cytotoxicity; Afssaps; Agence française de sécurité sanitaire des produits de santÃ
Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety
Keywords: monoclonal antibodies; clinical trials, phase I; clinical trials, phase II; clinical trials, phase IV; ADCC; antibody dependent cellular cytotoxicity; (ex-)Afssaps; ex-Agence française de sécurité sanitaire des produits de santé (at present french Nat